NCT07093931View on ClinicalTrials.gov

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2030

Conditions
Breast Cancer
Interventions
DRUG

lobaplatin

30mg / m2 i.v. q3w

DRUG

carboplatin

AUC 5-6 i.v. q3w

DRUG

Docetaxel or albumin paclitaxel

Docetaxel ( 75 mg / m2 i.v. d1, q3w ) or albumin paclitaxel ( 260 mg / m2 i.v. d1, q3w )

DRUG

Trastuzumab

6 cycles of treatment, according to the instructions recommended dosage.

DRUG

pertuzumab

6 cycles of treatment, according to the instructions recommended dosage.

Trial Locations (1)

250117

Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong

All Listed Sponsors
collaborator

Cancer Hospital Chinese Academy of Medical Science

UNKNOWN

lead

Shandong Cancer Hospital and Institute

OTHER